|
US2005221411A1
|
|
Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
|
|
US2005137209A1
|
|
Treatment of neurologic disorders with inhibitors of 11beta-HSD1
|
|
US2005142630A1
|
|
Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
|
|
US2005123962A1
|
|
Regulated nucleic acids in pathogenesis of alzheimer's disease
|
|
US2005106745A1
|
|
Combination of solubility and membrane permeability measurement methods for profiling of chemical compounds
|
|
US2005266509A1
|
|
Interaction of NMDA receptor with protein tyrosine phosphatase
|
|
WO2005012551A2
|
|
Interaction of nmda receptor with protein tyrosine phosphatase
|
|
CN1802168A
|
|
Sigma ligands for neuronal regeneration and functional recovery
|
|
WO2004064768A2
|
|
Animal model for alzheimer's disease
|
|
US6977142B2
|
|
High-throughput turbidometric assay for screening inhibitors of protein disulfide isomerase activity
|
|
US7060275B2
|
|
Use of protein biomolecular targets in the treatment and visualization of brain tumors
|
|
EP1495130A1
|
|
Use of biomolecular targets in the treatment and visualization of brain tumors
|
|
US2006024233A1
|
|
Use of biomolecular targets in the treatment and visualization of brain tumors
|
|
US6846641B2
|
|
In vitro ischemia model
|
|
US6924109B2
|
|
High-throughput transcriptome and functional validation analysis
|
|
CA2439630A1
|
|
Use of biomolecular targets in the treatment and visualization of brain tumors
|
|
US2002172958A1
|
|
Method of diagnosing ischemic stroke via UCP-2 detection
|
|
US2003027168A1
|
|
High-throughput transcriptome and functional validation analysis
|
|
AU3659101A
|
|
Interaction of NMDA receptor with protein tyrosine phosphatase
|
|
US6660483B1
|
|
Diagnostic marker for neurological conditions
|
